{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:11:19Z","timestamp":1791090679907,"version":"4.1.0"},"reference-count":65,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2014,2,27]],"date-time":"2014-02-27T00:00:00Z","timestamp":1393459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:p>\n                    Dasatinib is a second generation tyrosine kinase inhibitor, with activity in imatinib resistant Ph\u2010positive ALL. We have treated 34 patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200919) or lymphoid blast phase of chronic myelogenous leukemia (CML\u2010LB) (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200915) with the combination of dasatinib and the hyperCVAD regimen. Prior regimens included hyperCVAD plus imatinib (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200911, 4 had transplant in first CR), other combination chemotherapy (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200912), monotherapy with kinase inhibitors other than dasatinib (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20099), and investigational agents (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20092). Pretreatment\n                    <jats:italic>ABL<\/jats:italic>\n                    mutations were noted in 10 patients. The overall response rate was 91%, with 24 patients (71%) achieving complete response (CR), and 7(21%) CR with incomplete platelet recovery (CRp). Two patients died during induction and one had progressive disease. Twenty\u2010six patients (84%) achieved complete cytogenetic remission after one cycle of therapy. Overall, 13 patients (42%) achieved complete molecular response, and 11 patients (35%) had major molecular response (\n                    <jats:italic>BCR\u2010ABL\/ABL<\/jats:italic>\n                    &lt;0.1%). Nine patients proceeded to allogeneic transplantation. Grades 3 and 4 toxicities included hemorrhage, pleural and pericardial effusions and infections. The median follow\u2010up for patients with CML\u2010LB is 37.5 months (range, 7\u201370 months) with a 3\u2010year overall survival of 70%; 68% remained in CR at 3 years. For ALL patients, the median follow\u2010up is 52 months (range, 45\u201359 months) with a 3\u2010year survival of 26%; 30% remain in CR at 3 years. The combination of HyperCVAD regimen with dasatinib is effective in patients with relapsed Ph\u2010positive ALL and CML\u2010LB. Am. J. Hematol. 89:282\u2013287, 2014. \u00a9 2013 Wiley Periodicals, Inc.\n                  <\/jats:p>","DOI":"10.1002\/ajh.23624","type":"journal-article","created":{"date-parts":[[2013,11,8]],"date-time":"2013-11-08T11:40:32Z","timestamp":1383910832000},"page":"282-287","source":"Crossref","is-referenced-by-count":64,"title":["Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia"],"prefix":"10.1002","volume":"89","author":[{"given":"Ohad","family":"Benjamini","sequence":"first","affiliation":[{"name":"Department of Leukemia University of Texas \u2013 MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa Liu","family":"Dumlao","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas \u2013 MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas \u2013 MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas \u2013 MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia\u2010Manero","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas \u2013 MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas \u2013 MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"Department of Hematopathology University of Texas \u2013 MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajyalakshmi","family":"Luthra","sequence":"additional","affiliation":[{"name":"Department of Hematopathology University of Texas \u2013 MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Garris","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas \u2013 MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas \u2013 MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"additional","affiliation":[{"name":"Department of Cellular Therapy and Stem Cell Transplantation University of Texas \u2013 MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Champlin","sequence":"additional","affiliation":[{"name":"Department of Cellular Therapy and Stem Cell Transplantation University of Texas \u2013 MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas \u2013 MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas \u2013 MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas \u2013 MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Department of Leukemia University of Texas \u2013 MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,2,27]]},"reference":[{"key":"e_1_2_5_2_1","first-page":"3983","article-title":"Prospective karyotype analysis in adult acute lymphoblastic leukemia: The cancer and leukemia Group B experience","volume":"93","author":"Wetzler M","year":"1999","journal-title":"Blood"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11664"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-149286"},{"key":"e_1_2_5_5_1","first-page":"196","article-title":"Philadelphia positive acute lymphoblastic leukemia in adults: Age distribution, BCR breakpoint and prognostic significance","volume":"5","author":"Secker\u2010Walker LM","year":"1991","journal-title":"Leukemia"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1536"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cco.0000245317.82391.1b"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.2.415.415"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01715353"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025"},{"key":"e_1_2_5_12_1","first-page":"3135","article-title":"A Collaborative Study of the Group Francais de Cytogenetique Hematologique","volume":"87","author":"Cytogenetic abnormalities in adult acute lymphoblastic leukemia: Correlations with hematologic findings outcome","year":"1996","journal-title":"Blood"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2053.x"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009148847"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0704"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200004063421402"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.015974"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-199380"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404320"},{"key":"e_1_2_5_20_1","first-page":"1","article-title":"Berlin, Germany, June 4\u20137, 2009","volume":"94","author":"14th Congress of the European Hematology Association","year":"2009","journal-title":"Haematologica"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.2177"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-011908"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.011221"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1287"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4386"},{"key":"e_1_2_5_26_1","first-page":"173","article-title":"Long\u2010term outcome of 335 adult patients receiving different schedules of imatinib and chemotherapy as front\u2010line treatment for Philadelphia\u2010Positive Acute Lymphoblastic Leukemia (Ph+ ALL)","volume":"116","author":"Pfeifer H","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_5_27_1","first-page":"169","article-title":"Imatinib significantly enhances long\u2010term outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII\/ECOG2993 Trial","volume":"116","author":"Fielding AK","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2958"},{"issue":"15","key":"e_1_2_5_29_1","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1200\/jco.2010.28.15_suppl.6506","article-title":"Long\u2010term outcome after hyper\u2010CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome\u2010positive acute lymphoblastic leukemia (Ph\u2010ALL)","volume":"28","author":"Thomas DA","year":"2010","journal-title":"J Clin Oncol"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0092"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-052373"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1343"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0606509103"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-073528"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20668"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800026"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23666"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1525-1578(10)60516-8"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401364"},{"key":"e_1_2_5_44_1","first-page":"371","article-title":"Management of Philadelphia chromosome\u2013positive acute lymphoblastic leukemia (Ph+ ALL)","author":"Ottmann OG","year":"2009","journal-title":"ASH Education Program Book"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.2514"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705148"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0181"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402770"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200104053441402"},{"key":"e_1_2_5_51_1","first-page":"692","article-title":"Dissecting the complexity of Philadelphia\u2010positive mutated populations by ultra\u2010deep sequencing of the Bcr\u2010Abl kinase domain: Biological and clinical implications","volume":"120","author":"Soverini S","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214221"},{"key":"e_1_2_5_53_1","first-page":"2144","article-title":"A pilot study of the combination of Nilotinib and Hyper\u2010CVAD for Philadelphia Chromosome Positive Acute Lymphocytic Leukemia and Lymphoid Blast Crisis Chronic Myelogenous Leukemia","volume":"116","author":"Castillo E","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_5_54_1","article-title":"Dasatinib efficacy in patients with imatinib\u2010resistant\/\u2010intolerant Philadelphia\u2010chromosome\u2010positive acute lymphoblastic leukemia: 24\u2010month data from START\u2010L","volume":"93","author":"Porkka K","year":"2008","journal-title":"Haematologica"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21615"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-351403"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-261586"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-301267"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001625728"},{"key":"e_1_2_5_60_1","first-page":"4674","article-title":"Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome\u2010positive acute leukemias treated with imatinib mesylate","volume":"9","author":"Pfeifer H","year":"2003","journal-title":"Clin Cancer Res"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03881.x"},{"key":"e_1_2_5_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140665"},{"key":"e_1_2_5_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.4.1094"},{"key":"e_1_2_5_64_1","first-page":"1453","article-title":"Detection of minimal residual leukemia predicts the outcome of patients with Philadelphia\u2010chromosome positive acute lymphoblastic leukemia treated with tyrosine kinase inhibitors plus chemotherapy","volume":"118","author":"Ravandi F","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.03988.x"},{"key":"e_1_2_5_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07377.x"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.23624","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.23624","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T06:24:59Z","timestamp":1696573499000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.23624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,27]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1002\/ajh.23624"],"URL":"https:\/\/doi.org\/10.1002\/ajh.23624","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,27]]}}}